<DOC>
	<DOCNO>NCT01475838</DOCNO>
	<brief_summary>This study evaluate non-inferiority Stribild® ( elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate ( E/C/F/TDF ) ) single-tablet regimen ( STR ) relative regimen consist protease inhibitor ( PI ) boost ritonavir ( RTV ) plus Truvada® ( FTC/TDF ) fixed-dose combination maintain HIV-1 RNA &lt; 50 copies/mL Week 48 virologically suppress , HIV-1 infect adult . This study also evaluate safety , tolerability , efficacy two regimens 96 week treatment .</brief_summary>
	<brief_title>Study Evaluate Switching From Regimens Consisting Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen Virologically Suppressed , HIV-1 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Ability understand sign write informed consent form Be stable antiretroviral regimen consist ritonavir boost PI plus FTC/TDF continuously ≥ 6 consecutive month precede screen visit Be first second antiretroviral drug regimen document undetectable plasma HIV 1 RNA level ≥ 6 month precede screen visit No previous use approve experimental integrase strand transfer inhibitor ( INSTI ) length time Documented historical genotype prior start initial antiretroviral therapy show know resistance TDF FTC HIV RNA &lt; 50 copies/mL screen Normal ECG Hepatic transaminases ≤ 5 × upper limit normal range ( ULN ) Total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin Adequate hematologic function Serum amylase ≤ 5 × ULN Estimated glomerular filtration rate ≥ 70 mL/min Females childbearing potential must agree utilize highly effective contraception method , nonheterosexually active , practice sexual abstinence screen throughout duration study period 30 day follow last dose study drug Female participant utilize hormonal contraceptive one birth control method must use method least three month prior study dose Male participant must agree utilize highly effective method contraception heterosexual intercourse screen visit , throughout duration study 30 day follow discontinuation investigational medicinal product , must nonheterosexually active , practice sexual abstinence Age ≥ 18 year A new AIDSdefining condition diagnose within 30 day prior screen Females breastfeed Positive serum pregnancy test ( female childbearing potential ) Receiving drug treatment hepatitis C , participant anticipate receive treatment hepatitis C course study Experiencing decompensated cirrhosis Have implant defibrillator pacemaker Current alcohol substance abuse would interfere compliance A history malignancy within past 5 year ongoing malignancy cutaneous Kaposi 's sarcoma , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma Active , serious infection require parenteral antibiotic antifungal therapy within 30 day prior Baseline , except intramuscular penicillin treatment syphilis Have treat immunosuppressant therapy chemotherapeutic agent within 3 month study screening , expect receive agent systemic steroid study Receiving ongoing therapy medication , include drug use elvitegravir , cobicistat , FTC , TDF ; know allergy excipients E/C/F/TDF tablet , FTC/TDF tablets No anticipated need initiate drug study contraindicate Receiving investigational drug Participation clinical trial Any clinical condition prior therapy would make participant unsuitable study unable comply dosing requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>